SAN FRANCISCO, CA, Biotech and medical AI innovator Surge announced a $2.6 million pre-seed financing round.
The round was co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley. Veteran angel investors, including Nicolas Godin, the COO/CFO of Cardiologs, also participated in the round. Surge was awarded the 2022 iLab grant, along with other non dilutive grants to complete the fundraising.
Surge is a biotech company focused on optimizing treatment for patients undergoing surgery. Our multidisciplinary team has developed a test to identify patients at risk for complications. By anticipating surgical risks to enable personalization of the care pathway, this innovation will revolutionize the patient experience and shift the standard of surgical care. Our team shares a common vision for healthcare innovation: to develop patient-focused solutions that benefit the entire healthcare system.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about